PAR Drugs board approved audited FY26 results with standalone net profit of ₹1,310.86 lakh, down 27% YoY.
Auditor issued unmodified opinion but highlighted SEBI order restraining proposed business transfer as a key audit matter.
Company renewed banking facility of ₹161 lakh and approved investments in liquid funds up to ₹90 crore.
Board declared a 10% bonus payment to employees totaling ₹25.14 lakh for FY25-26.